| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/26/2002 | CA2440623A1 Methods involving the use of capg as a diagnostic marker and methods for the identification of capg modulators for the treatment and prevention of osteoporosis and related diseasestates |
| 09/26/2002 | CA2440391A1 Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells |
| 09/26/2002 | CA2439530A1 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| 09/26/2002 | CA2404581A1 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 09/25/2002 | EP1243290A2 Modulation of gene expression by combination therapy |
| 09/25/2002 | EP1243289A2 Modulation of gene expression by combination therapy |
| 09/25/2002 | EP1243273A1 Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters |
| 09/25/2002 | EP1243270A1 Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
| 09/25/2002 | EP1243258A1 Production of a preparation comprising one or more antibiotics |
| 09/25/2002 | EP1243257A1 Sustained release preparation comprising one or more antibiotics |
| 09/25/2002 | EP1243255A2 Method of preparation of antibiotic compositions |
| 09/25/2002 | EP1243252A1 Skin composition containing fibres and ubiquinones |
| 09/25/2002 | EP1242822A2 Methods of detection of amyloidogenic proteins |
| 09/25/2002 | EP1242624A2 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 09/25/2002 | EP1242617A2 Method of classifying a thyroid carcinoma using differential gene expression |
| 09/25/2002 | EP1242611A2 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 09/25/2002 | EP1242608A2 Method of achieving persistent transgene expression |
| 09/25/2002 | EP1242590A2 Human lyases and associated proteins |
| 09/25/2002 | EP1242585A1 IDENTIFICATION OF NOVEL SPLICE VARIANTS OF THE HUMAN CATALYTIC SUBUNIT C BETA OF cAMP-DEPENDENT PROTEIN KINASE AND THE USE THEREOF |
| 09/25/2002 | EP1242584A2 Human kinases |
| 09/25/2002 | EP1242583A2 Human oxidoreductase proteins |
| 09/25/2002 | EP1242456A2 Scfv antibodies against disease associated molecules |
| 09/25/2002 | EP1242447A1 Compounds and use thereof to modify transport across cell membranes |
| 09/25/2002 | EP1242436A2 Oligosaccharide mixture |
| 09/25/2002 | EP1242435A2 Medicaments for treatment of respiratory syncytial virus infections |
| 09/25/2002 | EP1242432A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 09/25/2002 | EP1242431A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 09/25/2002 | EP1242426A1 Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors |
| 09/25/2002 | EP1242421A1 4-[aryl(8-azabicyclo[3.2.1] octan-3-yl)] aminobenzoic acid derivatives |
| 09/25/2002 | EP1242407A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242403A1 2,4-diaminopyrimidine compounds usful as immunosuppressants |
| 09/25/2002 | EP1242385A1 Cytokine, especially tnf-alpha, inhibitors |
| 09/25/2002 | EP1242383A1 Aza compounds having neuronal activity |
| 09/25/2002 | EP1242371A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242122A2 Delivery of proteins across polar epithelial cell layers |
| 09/25/2002 | EP1242120A2 Combinations of growth factors and i:upa or i:mmp for the treatment of damaged tissue |
| 09/25/2002 | EP1242119A2 Combinations for the treatment of dna viral infections comprising a loop diuretic and a cardiac glycoside |
| 09/25/2002 | EP1242118A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 09/25/2002 | EP1242110A1 A method and composition for treating prostate cancer |
| 09/25/2002 | EP1242097A2 Pharmaceutical composition comprising a vanadium compound and at least a component selected from a na+/h+ exchanger, cyclo-oxygenase inhibitors and caspase inhibitors |
| 09/25/2002 | EP1242096A2 Combinations for the treatment of dna viral infections comprising a loop diuretic and lithium |
| 09/25/2002 | EP1242095A1 Antimicrobial compositions and methods of use |
| 09/25/2002 | EP1242094A1 Methods for treating mild cognitive impairment |
| 09/25/2002 | EP1242093A1 A method of treating substance addiction |
| 09/25/2002 | EP1242092A2 Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug |
| 09/25/2002 | EP1242090A1 Use of h1 antagonist and a safe steroid to treat eye conditions |
| 09/25/2002 | EP1242087A2 Analgesic compositions containing buprenorphine |
| 09/25/2002 | EP1242085A1 Benzimidazole compounds having nociceptin receptor affinity |
| 09/25/2002 | EP1242082A1 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 09/25/2002 | EP1242078A2 Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats |
| 09/25/2002 | EP1242069A2 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 09/25/2002 | EP1242068A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 09/25/2002 | EP1242063A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 09/25/2002 | EP1242060A1 Treatment of metastatic disease |
| 09/25/2002 | EP1242058A1 Use of cyp2d6 inhibitors in combination therapies |
| 09/25/2002 | EP1242050A2 Survivin promotion of angiogenesis |
| 09/25/2002 | EP1242049A1 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 09/25/2002 | EP1242048A1 Inhalation particles |
| 09/25/2002 | EP1242009A1 Tissue sensitizing compounds for females with methods and apparatus for the delivery of these compounds |
| 09/25/2002 | EP1241943A1 Use of polysiloxanes containing quaternary amino groups as formulation auxiliary agents, and agents containing the same |
| 09/25/2002 | EP1089761B1 Medicaments containing bisphosphonic acids and derivatives thereof which are provided for preventing and treating autoimmune diseases and allergies |
| 09/25/2002 | EP0980263B1 Combined product associating a nucleic acid with a substance breaking up the extracellular matrix for gene therapy |
| 09/25/2002 | EP0977559B1 Enhanced anti-cancer agent delivery to solid tumors by primer compounds |
| 09/25/2002 | EP0972020B1 Insulin-like growth factor agonist molecules |
| 09/25/2002 | EP0942751B1 Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
| 09/25/2002 | EP0918540B1 Intradermal bovine polynucleotide vaccine |
| 09/25/2002 | CN1371421A Tankyrase 2 materials and methods |
| 09/25/2002 | CN1371391A Heparin compositions that inhibit clot associated coagulation factors |
| 09/25/2002 | CN1371390A Human G-protein coupled receptor |
| 09/25/2002 | CN1371371A Novel derivatives of flavones, xanthones and coumarins |
| 09/25/2002 | CN1371359A Aminobenzophenones as inhibitors IL-1 beta and TNF-alpha |
| 09/25/2002 | CN1371291A Method and formula for tumor remission and suppression of cancer |
| 09/25/2002 | CN1371287A Preserved pharmaceutical formulations |
| 09/25/2002 | CN1371286A Use of cyclooxygenase-2 inhibitor matrix metallappoteinase inhibitor antineoplastic agent and optionally radiation as combination treatment of neoplasia |
| 09/25/2002 | CN1371280A Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 09/25/2002 | CN1370535A Method of inhibiting skin damage of vitamin A analog |
| 09/25/2002 | CN1370531A Combined therapy |
| 09/25/2002 | CN1091363C 脂肪掺合物 Fat blend |
| 09/24/2002 | US6455686 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 09/24/2002 | US6455674 Polypeptide for use in the diagnosis and treatment of tissue oxygenation defects |
| 09/24/2002 | US6455593 Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
| 09/24/2002 | US6455586 Human contact sensitizers; vehicles consisting of non-volatile, nonionic surfactants and esters of isopropyl alcohol and myristic acid and palmitic acid |
| 09/24/2002 | US6455582 Treating cancer |
| 09/24/2002 | US6455569 Connective tissue softening |
| 09/24/2002 | US6455568 Combination therapy for inhibiting sphincter incontinence |
| 09/24/2002 | US6455564 Oral administration of (5r)-(methylamino)-5,6-dihydro-4h-imidazo(4,5,1-ij)quinolin-2( '1h)-one or -thione |
| 09/24/2002 | US6455562 Cyclic AMP-specific phosphodiesterase inhibitors |
| 09/24/2002 | US6455553 Method for treating a demyelinating condition |
| 09/24/2002 | US6455552 Combination of a GABAA α5 inverse agonist and a muscarinic agonist |
| 09/24/2002 | US6455544 Use of cholinesterase inhibitors to treat disorders of attention |
| 09/24/2002 | US6455537 Methods for treating opiate intolerance |
| 09/24/2002 | US6455536 Treatment of dyskinesia |
| 09/24/2002 | US6455527 High affinity ligands for nociceptin receptor ORL-1 |
| 09/24/2002 | US6455524 Medicament compositions based on anticholinergically-effective compounds and beta-mimetics |
| 09/24/2002 | US6455518 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
| 09/24/2002 | US6455502 Compounds and compositions as protease inhibitors |
| 09/24/2002 | US6455291 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/24/2002 | US6455290 Tankyrase homolog protein (THP), nucleic acids, and methods related to the same |